Drug Profile


Alternative Names: RGH-896; UCB-3491

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Gedeon Richter
  • Developer Forest Laboratories; Gedeon Richter; PRA Health Sciences; UCB
  • Class Non-opioid analgesics; Small molecules
  • Mechanism of Action NMDA receptor antagonists; NR2B N-Methyl-D-Aspartate antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Epilepsy; Pain
  • Preclinical Parkinson's disease
  • Discontinued Neuropathic pain

Most Recent Events

  • 11 Jul 2016 UCB Biopharma plans a phase II trial for Infantile spasms in Belgium and United Kingdom (PO) (NCT02829827)
  • 16 Feb 2016 Preclinical data released by UCB Pharma
  • 01 Feb 2016 UCB Biopharma completes a phase I trial in Pain (In volunteers) in the Netherlands (NCT02647697)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top